But we've continued to innovate. HR+ cancer, treatable with anti-estrogen drugs, received a huge boost in the r/r setting with CDK4 inhibitors:
April 5, 2026 at 2:42 AM
But we've continued to innovate. HR+ cancer, treatable with anti-estrogen drugs, received a huge boost in the r/r setting with CDK4 inhibitors:
Delighted to share our latest work showing how cells that evade #senescence after CDK4/6 inhibition are primed to become aneuploid because of their increased size (due to defects in cohesion and the mitotic checkpoint). Great work by fab PhD student Aanchal Pareri 👏🧪
www.biorxiv.org/content/10.1...
www.biorxiv.org/content/10.1...
Cell enlargement causes mitotic errors and aneuploidy in cells that evade senescence after CDK4/6 inhibition
CDK4/6 inhibitors (CDK4/6i) arrest the cell cycle in G1 leading to cellular overgrowth and p53-dependent senescence. They are used to treat metastatic HR+/HER2- breast cancer, but resistance is common...
www.biorxiv.org
July 3, 2025 at 7:17 AM
Delighted to share our latest work showing how cells that evade #senescence after CDK4/6 inhibition are primed to become aneuploid because of their increased size (due to defects in cohesion and the mitotic checkpoint). Great work by fab PhD student Aanchal Pareri 👏🧪
www.biorxiv.org/content/10.1...
www.biorxiv.org/content/10.1...
What to do here? Current SOC is endocrine therapy + CDK4/6 inhibitor but SONIA showed that endocrine therapy alone may be just as good, adding a CDK4/6i later with progression - and preserves QOL better, including lessening financial toxicity. #SABCS24
December 11, 2024 at 10:11 PM
What to do here? Current SOC is endocrine therapy + CDK4/6 inhibitor but SONIA showed that endocrine therapy alone may be just as good, adding a CDK4/6i later with progression - and preserves QOL better, including lessening financial toxicity. #SABCS24
Exciting news in cancer therapy! The order of drugs impacts the duration of treatment, toxicity, and economic cost. A necessary example of how relevant academic, self-funded trials are!!
Breast #cancer #oncosky #oncsky #medsky 🧪 @natureportfolio.bsky.social www.nature.com/articles/d41...
Breast #cancer #oncosky #oncsky #medsky 🧪 @natureportfolio.bsky.social www.nature.com/articles/d41...
Toxicity and costs of cancer treatment reduced by deferring CDK4/6 inhibitor use
No difference in survival outcomes between use of CDK4/6 inhibitors as first- or second-line treatment in metastatic breast cancer.
www.nature.com
November 27, 2024 at 7:21 PM
Exciting news in cancer therapy! The order of drugs impacts the duration of treatment, toxicity, and economic cost. A necessary example of how relevant academic, self-funded trials are!!
Breast #cancer #oncosky #oncsky #medsky 🧪 @natureportfolio.bsky.social www.nature.com/articles/d41...
Breast #cancer #oncosky #oncsky #medsky 🧪 @natureportfolio.bsky.social www.nature.com/articles/d41...
Practice change ALERT in the POST-CDK4/6 HR+, HER2- space.
The selective estrogen-receptor degrader imlunestrant plus abemaciclib led to a median progression-free survival of 9.4 months among patients with ER-positive, HER2-negative breast cancer (vs. 5.5 months with imlunestrant alone). Full EMBER-3 trial results: nej.md/4fZ74HX
#MedSky #SABCS24
#MedSky #SABCS24
December 11, 2024 at 2:15 PM
Practice change ALERT in the POST-CDK4/6 HR+, HER2- space.
Wow!! 🔥🔥 CDK4/6 inhibition prevents selection of #ClonalHematopoiesis with DNA-damage repair mutations after chemotherapy! Awesome presentation from Irenaeus Chan from @kellybolton.bsky.social lab! #ASH25
December 7, 2025 at 8:28 PM
Wow!! 🔥🔥 CDK4/6 inhibition prevents selection of #ClonalHematopoiesis with DNA-damage repair mutations after chemotherapy! Awesome presentation from Irenaeus Chan from @kellybolton.bsky.social lab! #ASH25
Now online in JCO #postMonarch
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer Following Progression on CDK4/6 Inhibition: Results from the Phase III postMONARCH Trial ascopubs.org/doi/pdf/10.1... @oncoalert.bsky.social #oncsky
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer Following Progression on CDK4/6 Inhibition: Results from the Phase III postMONARCH Trial ascopubs.org/doi/pdf/10.1... @oncoalert.bsky.social #oncsky
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer Following Progression on CDK4/6 Inhibition: Results from the Phase III postMONARCH Trial
PURPOSECyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET)
are the standard first-line treatment for hormone receptor-positive (HR+), human epidermal
growth factor re...
ascopubs.org
December 22, 2024 at 10:31 PM
Now online in JCO #postMonarch
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer Following Progression on CDK4/6 Inhibition: Results from the Phase III postMONARCH Trial ascopubs.org/doi/pdf/10.1... @oncoalert.bsky.social #oncsky
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer Following Progression on CDK4/6 Inhibition: Results from the Phase III postMONARCH Trial ascopubs.org/doi/pdf/10.1... @oncoalert.bsky.social #oncsky
"CDK4 selective inhibition improves preclinical antitumor efficacy and safety" www.cell.com/cancer-cell/...
#Pfizer Lars Anders
@cp-cancercell.bsky.social
#Pfizer Lars Anders
@cp-cancercell.bsky.social
CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety
Palmer et al. report a next-generation CDK4-selective inhibitor, atirmociclib, with
enhanced anti-tumor activity and reduced predicted toxicity compared to FDA-approved
dual CDK4/6 inhibitors. Combina...
www.cell.com
March 13, 2025 at 3:02 PM
"CDK4 selective inhibition improves preclinical antitumor efficacy and safety" www.cell.com/cancer-cell/...
#Pfizer Lars Anders
@cp-cancercell.bsky.social
#Pfizer Lars Anders
@cp-cancercell.bsky.social
Check out our latest work on cell cycle inhibitors, which has implications for how cancer cells could become resistant to these drugs
#senescence #cellcycle #cancer 🧪
www.biorxiv.org/content/10.1...
#senescence #cellcycle #cancer 🧪
www.biorxiv.org/content/10.1...
Cell enlargement causes mitotic errors and aneuploidy in cells that evade senescence after CDK4/6 inhibition
CDK4/6 inhibitors (CDK4/6i) arrest the cell cycle in G1 leading to cellular overgrowth and p53-dependent senescence. They are used to treat metastatic HR+/HER2-breast cancer, but resistance is common,...
www.biorxiv.org
July 25, 2025 at 4:37 PM
Check out our latest work on cell cycle inhibitors, which has implications for how cancer cells could become resistant to these drugs
#senescence #cellcycle #cancer 🧪
www.biorxiv.org/content/10.1...
#senescence #cellcycle #cancer 🧪
www.biorxiv.org/content/10.1...
New Paper Alert! HR+ Breast Cancer: Efficacy of Subsequent Treatments After CDK4/6 Inhibitor Progression
oncodaily.com/oncolibrary/...
#ASCO #Cancer #CancerCare #CancerResearch #Headlines #JCO #JCOOncology #Practice #NewPaperAlert #Medicine #Health
oncodaily.com/oncolibrary/...
#ASCO #Cancer #CancerCare #CancerResearch #Headlines #JCO #JCOOncology #Practice #NewPaperAlert #Medicine #Health
New Paper Alert! HR+ Breast Cancer: Efficacy of Subsequent Treatments After CDK4/6 Inhibitor Progression - OncoDaily
Meta-analysis on post-CDK4/6 inhibitor treatment for HR+ breast cancer, revealing how continuing or switching CDK4/6 inhibitors boosts survival.
oncodaily.com
December 26, 2024 at 8:39 PM
New Paper Alert! HR+ Breast Cancer: Efficacy of Subsequent Treatments After CDK4/6 Inhibitor Progression
oncodaily.com/oncolibrary/...
#ASCO #Cancer #CancerCare #CancerResearch #Headlines #JCO #JCOOncology #Practice #NewPaperAlert #Medicine #Health
oncodaily.com/oncolibrary/...
#ASCO #Cancer #CancerCare #CancerResearch #Headlines #JCO #JCOOncology #Practice #NewPaperAlert #Medicine #Health
CDK4/6 inhibitors: mechanisms of resistance and where to find them.
An outside of the box review
Main takeaways:
🛑RB1 loss in #ctDNA predicts poorer PFS
⚠️CCNE1 gain impacts PALOMA-3 outcomes
🧩Role of ESR1 still unclear
Read more👇
www.sciencedirect.com/science/arti...
#bcsm #BreastCancer
An outside of the box review
Main takeaways:
🛑RB1 loss in #ctDNA predicts poorer PFS
⚠️CCNE1 gain impacts PALOMA-3 outcomes
🧩Role of ESR1 still unclear
Read more👇
www.sciencedirect.com/science/arti...
#bcsm #BreastCancer
Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i): mechanisms of resistance and where to find them
CDK4/6 inhibitors (CDK4/6i) have significantly impacted on the treatment of HR+ HER2 negative (HER2-) metastatic breast cancer (BC) when combined with…
www.sciencedirect.com
December 20, 2024 at 7:50 AM
CDK4/6 inhibitors: mechanisms of resistance and where to find them.
An outside of the box review
Main takeaways:
🛑RB1 loss in #ctDNA predicts poorer PFS
⚠️CCNE1 gain impacts PALOMA-3 outcomes
🧩Role of ESR1 still unclear
Read more👇
www.sciencedirect.com/science/arti...
#bcsm #BreastCancer
An outside of the box review
Main takeaways:
🛑RB1 loss in #ctDNA predicts poorer PFS
⚠️CCNE1 gain impacts PALOMA-3 outcomes
🧩Role of ESR1 still unclear
Read more👇
www.sciencedirect.com/science/arti...
#bcsm #BreastCancer
The @oncbrothers.bsky.social are discussing the adjuvant CDK4/6 inhibitor landscape, Drs @laurahuppert.bsky.social and @neil-iyengarmd.bsky.social agree shared decision making with patients in key. #SABCS24
December 12, 2024 at 1:50 AM
The @oncbrothers.bsky.social are discussing the adjuvant CDK4/6 inhibitor landscape, Drs @laurahuppert.bsky.social and @neil-iyengarmd.bsky.social agree shared decision making with patients in key. #SABCS24
Delaying and shortening the duration of treatment with CDK4/6 inhibitors in patients with metastatic breast cancer leads to similar survival outcomes while reducing toxicity and achieving substantial cost savings, the SONIA trial shows. Read more ➡️ bit.ly/3Oqw7aX
November 27, 2024 at 4:45 PM
Delaying and shortening the duration of treatment with CDK4/6 inhibitors in patients with metastatic breast cancer leads to similar survival outcomes while reducing toxicity and achieving substantial cost savings, the SONIA trial shows. Read more ➡️ bit.ly/3Oqw7aX
Out in @ESMO_Open by @hoperugo.bsky.social et al real-world data on CDK4/6i in #breastcancer 🌎
No significant OS difference between 1L palbo, ribo, and abema
Are CDK4/6i equal? Do OS differences in randomized trials depend on study design?
@oncoalert.bsky.social
www.esmoopen.com/article/S205...
No significant OS difference between 1L palbo, ribo, and abema
Are CDK4/6i equal? Do OS differences in randomized trials depend on study design?
@oncoalert.bsky.social
www.esmoopen.com/article/S205...
Comparative overall survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR+/HER2− metastatic breast cancer in the US real-world setting☆
Randomized controlled trials have shown inconsistent overall survival (OS) benefit
among the three cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) as first-line (1L)
treatment of patients with hormon...
www.esmoopen.com
January 18, 2025 at 9:18 AM
Out in @ESMO_Open by @hoperugo.bsky.social et al real-world data on CDK4/6i in #breastcancer 🌎
No significant OS difference between 1L palbo, ribo, and abema
Are CDK4/6i equal? Do OS differences in randomized trials depend on study design?
@oncoalert.bsky.social
www.esmoopen.com/article/S205...
No significant OS difference between 1L palbo, ribo, and abema
Are CDK4/6i equal? Do OS differences in randomized trials depend on study design?
@oncoalert.bsky.social
www.esmoopen.com/article/S205...
SERENA-6 phase 3 trial: In patients with advanced breast cancer, switching to camizestrant with a CDK4/6 inhibitor after ESR1-mutation detection (and before disease progression) led to significantly longer progression-free survival. nej.md/4k1dRml
#ASCO25 @ascocancer.bsky.social
#ASCO25 @ascocancer.bsky.social
June 1, 2025 at 2:39 PM
SERENA-6 phase 3 trial: In patients with advanced breast cancer, switching to camizestrant with a CDK4/6 inhibitor after ESR1-mutation detection (and before disease progression) led to significantly longer progression-free survival. nej.md/4k1dRml
#ASCO25 @ascocancer.bsky.social
#ASCO25 @ascocancer.bsky.social
EMBER-3 Trial Updates from ESMO Breast 2025: Imlunestrant Plus Abemaciclib Improves PFS in CDK4/6i-Pretreated ER+/HER2- Breast Cancer
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #EMBER3 #ESMOBreast25 #BreastCancer #Imlunestrant #Abemaciclib
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #EMBER3 #ESMOBreast25 #BreastCancer #Imlunestrant #Abemaciclib
EMBER-3 Trial Updates from ESMO Breast 2025: Imlunestrant Plus Abemaciclib Improves PFS in CDK4/6i-Pretreated ER+/HER2- Breast Cancer - OncoDaily
ESMO Breast 2025: Imlunestrant + abemaciclib shows PFS benefit in CDK4/6i-pretreated ER+/HER2- advanced breast cancer, per EMBER-3 data.
oncodaily.com
May 15, 2025 at 10:34 PM
EMBER-3 Trial Updates from ESMO Breast 2025: Imlunestrant Plus Abemaciclib Improves PFS in CDK4/6i-Pretreated ER+/HER2- Breast Cancer
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #EMBER3 #ESMOBreast25 #BreastCancer #Imlunestrant #Abemaciclib
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #EMBER3 #ESMOBreast25 #BreastCancer #Imlunestrant #Abemaciclib
DAWNA-2 — phase 3 trial using CDK4/6i Dalpiciclib in 1L meets primary endpoint PFS #SABCS24 @oncoalert.bsky.social
December 12, 2024 at 1:41 PM
DAWNA-2 — phase 3 trial using CDK4/6i Dalpiciclib in 1L meets primary endpoint PFS #SABCS24 @oncoalert.bsky.social
Check out our new paper @jci.org
High 4E-BP-1 expression associates with chromosome 8 gain and CDK4/6 sensitivity in Ewing Sarcoma
www.jci.org/articles/vie...
We show that chr8 gains drive poor outcome in EwS via 4E-BP-1
@dkfz.bsky.social
@nct-heidelberg.bsky.social
@uniheidelberg.bsky.social
High 4E-BP-1 expression associates with chromosome 8 gain and CDK4/6 sensitivity in Ewing Sarcoma
www.jci.org/articles/vie...
We show that chr8 gains drive poor outcome in EwS via 4E-BP-1
@dkfz.bsky.social
@nct-heidelberg.bsky.social
@uniheidelberg.bsky.social
JCI -
High 4E-BP-1 expression associates with chromosome 8 gain and CDK4/6 sensitivity in Ewing Sarcoma
www.jci.org
October 17, 2025 at 6:31 PM
Check out our new paper @jci.org
High 4E-BP-1 expression associates with chromosome 8 gain and CDK4/6 sensitivity in Ewing Sarcoma
www.jci.org/articles/vie...
We show that chr8 gains drive poor outcome in EwS via 4E-BP-1
@dkfz.bsky.social
@nct-heidelberg.bsky.social
@uniheidelberg.bsky.social
High 4E-BP-1 expression associates with chromosome 8 gain and CDK4/6 sensitivity in Ewing Sarcoma
www.jci.org/articles/vie...
We show that chr8 gains drive poor outcome in EwS via 4E-BP-1
@dkfz.bsky.social
@nct-heidelberg.bsky.social
@uniheidelberg.bsky.social
Now Surender Surender on stage, presenting our data on CDK4/6 inhibition in experimental glioma!
@eanoassociation.bsky.social
@ghtabatabai.bsky.social
@hih-tuebingen.bsky.social
@eanoassociation.bsky.social
@ghtabatabai.bsky.social
@hih-tuebingen.bsky.social
October 18, 2025 at 10:48 AM
Now Surender Surender on stage, presenting our data on CDK4/6 inhibition in experimental glioma!
@eanoassociation.bsky.social
@ghtabatabai.bsky.social
@hih-tuebingen.bsky.social
@eanoassociation.bsky.social
@ghtabatabai.bsky.social
@hih-tuebingen.bsky.social
#PADMA study presented by Dr. Loibl - looking at induction chemo followed by ET maint vs. upfront ET + CDk4/6 1st L
Another study....chemo inferior to ET + CDK4/6.
🆘 No need to do this folks. Chemo 🚫doesn't help us here.
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
#bcsm
Another study....chemo inferior to ET + CDK4/6.
🆘 No need to do this folks. Chemo 🚫doesn't help us here.
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
#bcsm
December 11, 2024 at 12:26 AM
#PADMA study presented by Dr. Loibl - looking at induction chemo followed by ET maint vs. upfront ET + CDk4/6 1st L
Another study....chemo inferior to ET + CDK4/6.
🆘 No need to do this folks. Chemo 🚫doesn't help us here.
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
#bcsm
Another study....chemo inferior to ET + CDK4/6.
🆘 No need to do this folks. Chemo 🚫doesn't help us here.
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
#bcsm
Fourth and final on HBO Max, The Strangers: Chapter 2. #filmsky #letterboxd #LastFourWatched
boxd.it/Cdk4
boxd.it/Cdk4
The Strangers: Chapter 2 (2025)
After learning that one of their victims, Maya, is still alive, The Strangers return to finish the job. With nowhere to run and no one to trust, Maya soon finds herself in a brutal fight for survival ...
boxd.it
September 26, 2026 at 6:14 AM
Fourth and final on HBO Max, The Strangers: Chapter 2. #filmsky #letterboxd #LastFourWatched
boxd.it/Cdk4
boxd.it/Cdk4
VERITAC-2 shows vepdegestrant improves PFS after CDK4/6i among pts with HR+ mutESR1 MBc, from 2.1 months to 5.0 months. @erikahamilton9.bsky.social
@oncoalert.bsky.social #ASCO25
@oncoalert.bsky.social #ASCO25
May 31, 2025 at 7:00 PM
VERITAC-2 shows vepdegestrant improves PFS after CDK4/6i among pts with HR+ mutESR1 MBc, from 2.1 months to 5.0 months. @erikahamilton9.bsky.social
@oncoalert.bsky.social #ASCO25
@oncoalert.bsky.social #ASCO25
SONIA trial - Pts with ER+ breast cancer beginning treatment in the metastatic setting randomized to 1st line vs 2nd line use of CDK4/6 inhibitor (+ endocrine therapy). No sig difference in PFS.
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer - Nature
The phase 3 SONIA trial challenges the benefits of using cyclin-dependent kinase 4 and 6 inhibitors as a first-line compared with second-line treatment.
www.nature.com
November 29, 2024 at 6:16 PM
SONIA trial - Pts with ER+ breast cancer beginning treatment in the metastatic setting randomized to 1st line vs 2nd line use of CDK4/6 inhibitor (+ endocrine therapy). No sig difference in PFS.
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Presenting phosphorylated FADD as a novel driver of resistance in breast cancer: doi.org/10.1172/JCI1...
Awadia et al. find that blocking FADD phosphorylation restored CDK4/6 inhibitor sensitivity and improved tumor control in resistant ER+ breast cancer models.
Awadia et al. find that blocking FADD phosphorylation restored CDK4/6 inhibitor sensitivity and improved tumor control in resistant ER+ breast cancer models.
September 28, 2026 at 3:02 PM
Presenting phosphorylated FADD as a novel driver of resistance in breast cancer: doi.org/10.1172/JCI1...
Awadia et al. find that blocking FADD phosphorylation restored CDK4/6 inhibitor sensitivity and improved tumor control in resistant ER+ breast cancer models.
Awadia et al. find that blocking FADD phosphorylation restored CDK4/6 inhibitor sensitivity and improved tumor control in resistant ER+ breast cancer models.